Paper
Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.
Published May 25, 2023 · D. Bhattacharya, A. Aronsohn, J. Price
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
105
Citations
3
Influential Citations
Abstract
The Infectious Diseases Society of America and the American Association for the Study of Liver Diseases have collaboratively developed evidence-based guidance regarding the diagnosis, management, and treatment of hepatitis C virus (HCV) infection since 2013. A panel of clinicians and investigators with extensive infectious diseases or hepatology expertise specific to HCV infection periodically review evidence from the field and update existing recommendations or introduce new recommendations as evidence warrants. This update focuses on changes to the guidance since the previous 2020 published update, including ongoing emphasis on recommended universal screening; management recommendations for incomplete treatment adherence; expanded eligibility for simplified chronic HCV infection treatment in adults with minimal monitoring; updated treatment and retreatment recommendations for children as young as 3 years old; management and treatment recommendations in the transplantation setting; and screening, treatment, and management recommendations for unique and key populations.
The updated AASLD-IDSA hepatitis C guidance emphasizes universal screening, expanded eligibility for simplified chronic treatment, updated treatment recommendations for children as young as 3, and unique populations.
Full text analysis coming soon...